Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: LemzoparlimabBiological: Daratumumab
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT04895410
- Locations
- 🇺🇸
Moffitt Cancer Center /ID# 229939, Tampa, Florida, United States
🇺🇸Norton Cancer Institute - St Matthews /ID# 229319, Louisville, Kentucky, United States
🇺🇸University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan, United States
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Skeletal Survey X-RayProcedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 37
- Registration Number
- NCT04883242
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04850599
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Selinexor, Pomalidomide, and Dexamethasone with or Without Carfilzomib for the Treatment of Patients with Relapsed Refractory Multiple Myeloma, the SCOPE Trial
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: X-Ray ImagingProcedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT04764942
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 52
- Registration Number
- NCT04756401
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 96
- Registration Number
- NCT04661137
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- European Myeloma Network B.V.
- Target Recruit Count
- 302
- Registration Number
- NCT04483739
- Locations
- 🇳🇱
Noordwest Ziekenhuisgroep Stichting - Internal Medicine - Hematology, Alkmaar, Netherlands
🇳🇱Amsterdam-Vrije Universiteit Medical Center (VUMC), Amsterdam, Netherlands
🇳🇱Amphia Hospital-Internal Medicine - Hematology, Breda, Netherlands
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 586
- Registration Number
- NCT04458831
- Locations
- 🇩🇪
Investigational Site Number : 2760003, Berlin, Germany
🇩🇪Investigational Site Number : 2760041, Berlin, Germany
🇫🇷Investigational Site Number : 2500011, Vannes Cedex, France
KRDI in Transplant-Eligible MM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04430894
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.